The double-edged flower: Roles of complement protein C1q in neurodegenerative diseases

Advances in Experimental Medicine and Biology

Volumn 586, Issue , 2006, Pages 153-176

  Tenner, Andrea J ^a   Fonseca, Maria I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84934437247     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-34134-X_11     Document Type: Conference Paper

References (130)

1. L.E. Hebert, P.A. Scherr, J.L. Bienias, D.A. Bennett, and D.A. Evans, Alzheimer's disease in the US population: prevalence estimates using the 2000 census, Arch Neurol 60, 1119-1122 (2003).
2. T.E. Golde, The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease, Brain Pathol 15, 84-87 (2005).
3. R.E. Tanzi and L. Bertram, Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective, Cell 120, 545-555 (2005).
4. D.M. Walsh, I. Klyubin, J.V. Fadeeva, W.K. Cullen, R. Anwyl, M.S. Wolfe, M.J. Rowan, and D.J. Selkoe, Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo, Nature 416, 535-539 (2002).
5. R.H. Takahashi, T.A. Milner, F. Li, E.E. Nam, M.A. Edgar, H. Yamaguchi, M.F. Beal, H. Xu, P. Greengard, and G.K. Gouras, Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology, Am J Pathol 161, 1869-1879 (2002).
6. M. Koistinaho, M. Ort, J.M. Cimadevilla, R. Vondrous, B. Cordell, J. Koistinaho, J. Bures, and L.S. Higgins, Specific spatial learning deficits become severe with age in beta-amyloid precursor protein transgenic mice that harbor diffuse beta-amyloid deposits but do not form plaques, Proc Natl Acad Sci USA 98, 14675-14680 (2001).
7. S. Oddo, A. Caccamo, J.D. Shepherd, M.P. Murphy, T.E. Golde, R. Kayed, R. Metherate, M.P. Mattson, Y. Akbari, and F.M. LaFerla, Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction, Neuron 39, 409-421 (2003).
8. M.A. Westerman, D. Cooper-Blacketer, A. Mariash, L. Kotilinek, T. Kawarabayashi, L.H. Younkin, G.A. Carlson, S.G. Younkin, and K.H. Ashe, The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease, J Neurosci 22, 1858-1867 (2002).
9. Y. Gong, L. Chang, K.L. Viola, P.N. Lacor, M.P. Lambert, C.E. Finch, G.A. Krafft, and W.L. Klein, Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss, Proc Natl Acad Sci USA 100, 10417-10422 (2003).
10. R. Kayed, E. Head, J.L. Thompson, T.M. McIntire, S.C. Milton, C.W. Cotman, and C.G. Glabe, Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis, Science 300, 486-489 (2003).
11. B. Urbanc, L. Cruz, R. Le, J.Sanders, K.H. Ashe, K. Duff, H.E. Stanley, M.C. Irizarry, and B.T. Hyman, Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease, Proc Natl Acad Sci USA 99, 13990-13995 (2002).
12. H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole, N.R. Cooper, P. Eikelenboom, M. Emmerling, B.L. Fiebich, C.E. Finch, S. Frautschy, W.S. Griffin, H. Hampel, M. Hull, G. Landreth, L. Lue, R. Mrak, I.R. Mackenzie, P.L. McGeer, M.K. O'Banion, J. Pachter, G. Pasinetti, C. Plata-Salaman, J. Rogers, R. Rydel, Y. Shen, W. Streit, R. Strohmeyer, I. Tooyoma, F.L. Van Muiswinkel, R. Veerhuis, D. Walker, S. Webster, B. Wegrzyniak, G. Wenk, and T. Wyss-Coray, Inflammation and Alzheimer's disease, Neurobiol Aging 21, 383-421 (2000).
13. R.L. Cotter, W.J. Burke, V.S. Thomas, J.F. Potter, J.L. Zheng, and H.E. Gendelman, Insights into the neurodegenerative process of Alzheimer's disease: a role for mononuclear phagocyte-associated inflammation and neurotoxicity, J Leuk Biol 65, 416-27 (1999).
14. B.J. Cummings, E. Head, A.J. Afagh, N.W. Milgram, and C.W. Cotman, Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine., Neurobiol Learning Memory 66, 11-23 (1996).
15. B.J. Cummings, C.J. Pike, R. Shankle, and C.W. Cotman, Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease [see comments], Neurobiol Aging 17, 921-933 (1996).
16. D.A. Bobak, T.G. Gaither, M.M. Frank, and A.J. Tenner, Modulation of FcR function by complement: subcomponent C1q enhances the phagocytosis of IgG-opsonized targets by human monocytes and culture-derived macrophages, J Immunol 138, 1150-1156 (1987).
17. P.R. Taylor, A. Carugati, V.A. Fadok, H.T. Cook, M. Andrews, M.C. Carroll, J.S. Savill, P.M. Henson, M. Botto, and M.J. Walport, A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo, J Exp Med 192, 359-366 (2000).
18. A. Sahu and J.D. Lambris, Structure and biology of complement protein C3, a connecting link between innate and acquired immunity, Immunol Rev 180, 35-48 (2001).
19. C1q in Alzheimer's disease brain, Exp Neurol 138, 22-32 (1996).
20. R. Strohmeyer, Y. Shen, and J. Rogers, Detection of complement alternative pathway mRNA and proteins in Alzheimer's disease brain., Mol Brain Res 81, 7-18 (2000).
21. H. Zanjani, C.E. Finch, C. Kemper, J. Atkinson, D. McKeel, J.C. Morris, and J.L. Price, Complement activation in very early Alzheimer disease, Alz Dis Assoc Disorders 19, 55-66 (2005).
22. P. Eikelenboom, C.E. Hack, J.M. Rozemuller, and F.C. Stam, Complement activation in amyloid plaques in Alzheimer's dementia, Virch Arch B Cell Pathol 56, 259-262 (1989).
23. P.L. McGeer, H. Akiyama, S. Itagaki, and E.G. McGeer, Immune system response in Alzheimer's disease, Can J Neurol Sci 16, 516-527 (1989).
24. Y. Shen, L. Lue, L.Yang, A. Roher, Y. Kuo, R. Strohmeyer, W.J. Goux, V. Lee, G.V. Johnson, S.D. Webster, N.R. Cooper, B. Bradt, and J. Rogers, Complement activation by neurofibrillary tangles in Alzheimer's disease, Neurosci Lett 305, 165-168 (2001).
25. S.A. Johnson, M. Lampert-Etchells, G.M. Pasinetti, I. Rozovsky, and C. Finch, Complement mRNA in the mammalian brain: Responses to Alzheimer's disease and experimental brain lesioning, Neurobiol Aging 13, 641-648 (1992).
26. Y. Shen, R. Li, E.G. McGeer, and P.L. McGeer, Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer's brain, Brain Res 769, 391-395 (1997).
27. S. Nataf, P.F. Stahel, N. Davoust, and S.R. Barnum, Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends Neurosci 22, 397-402 (1999).
28. S. Webster, L.F. Lue, L. Brachova, A.J. Tenner, P.L. McGeer, K. Terai, D.G. Walker, B. Bradt, N.R. Cooper, and J. Rogers, Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease, Neurobiol Aging 18, 415-421 (1997).
29. E. Head, B.Y. Azizeh, I.T. Lott, A.J. Tenner, C.W. Cotman, and D.H. Cribbs, Complement association with neurons and β-amyloid deposition in the brains of aged individuals with Down syndrome, Neurobiol Dis 8, 252-265 (2001).
30. M.I. Fonseca, C.H. Kawas, J.C. Troncoso, and A.J. Tenner, Neuronal localization of C1q in preclinical Alzheimer's disease, Neurobiol Dis 15, 40-46 (2004).
31. S.E. Stoltzner, T.J. Grenfell, C. Mori, K.E. Wisniewski, T.M. Wisniewski, D.J. Selkoe, and C.A. Lemere, Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease, Am J Pathol 156, 489-499 (2000).
32. J. Rogers, N.R. Cooper, S. Webster, J. Schultz, P.L. McGeer, S.D. Styren, W.H. Civin, L. Brachova, B. Bradt, P. Ward, and I. Lieberburg, Complement activation by beta-amyloid in Alzheimer disease., Proc Natl Acad Sci USA 89, 10016-10020 (1992).
33. H. Jiang, D. Burdick, C.G. Glabe, C.W. Cotman, and A.J. Tenner, β-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain, J Immunol 152, 5050-5059 (1994).
34. S. Chen, R.C. Frederickson, and K.R. Brunden, Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: complement activation and therapeutic approaches, Neurobiol Aging 17, 781-787 (1996).
35. B.M. Bradt, W.P. Kolb, and N.R. Cooper, Complement-dependent proinflammatory properties of the Alzheimer's disease β-peptide, J Exp Med 188, 431-438 (1998).
36. M.D. Watson, A.E. Roher, K.S. Kim, K. Spiegel, and M.R. Emmerling, Complement interactions with amyloid-β1-42: a nidus for inflammation in AD brains., Amyloid: Int J Exp Clin Invest 4, 147-156 (1997).
37. P. Velazquez, D.H. Cribbs, T.L. Poulos, and A.J. Tenner, Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis, Nature Med 3, 77-79 (1997).
38. S. Webster, B. Bradt, J. Rogers, and N.R. Cooper, Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide, J Neurochem 69, 388-398 (1997).
39. D.H. Cribbs, P. Velazquez, B. Soreghan, C.G. Glabe, and A.J. Tenner, Complement activation by cross-linked truncated and chimeric full-length β-amyloid, NeuroReport 8, 3457-3462 (1997).
40. S. Webster, C. Glabe, and J. Rogers, Multivalent binding of complement protein C1q to the amyloid β-peptide (Aβ) promotes the nucleation phase of Aβ aggregation, Biochem Biophys Res Commun 217, 869-875 (1995).
41. P. Tacnet-Delorme, S. Chevallier, and G.J. Arlaud, Beta-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for A beta on the C1q globular regions, J Immunol 167, 6374-6381 (2001).
42. C. Gaboriaud, J. Juanhuix, A. Gruez, M. Lacroix, C. Darnault, D. Pignol, D. Verger, J.C. Fontecilla-Camps, and G.J. Arlaud, The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties, J Biol Chem 278, 46974-46982 (2003).
43. J. Yao, L. Harvath, D.L. Gilbert, and C.A. Colton, Chemotaxis by a CNS macrophage, the microglia, J Neurosci Res 27, 36-42 (1990).
44. A.J. Tenner and S.D. Webster. "Complement-mediated injury and inflammation in the pathogenesis of Alzheimer's Disease." In Inflammatory events in neurodegeneration, eds., S.C. Bondy and A. Campbell, pp. 119-138. Scottsdale, AZ: Prominent Press (2001).
45. A.J. Tenner, Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events, Neurobiol Aging 22, 849-861 (2001).
46. K. Yasojima, E.G. McGeer, and P.L. McGeer, Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease, Brain Res 833, 297-301 (1999).
47. C. Sturchler-Pierrat, D. Abramowski, M. Duke, K.H. Wiederhold, C. Mistl, S. Rothacher, B. Ledermann, K. Burki, P. Frey, P.A. Paganetti, C. Waridel, M.E. Calhoun, M. Jucker, A. Probst, M. Staufenbiel, and B. Sommer, Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology, Proc Natl Acad Sci USA 94, 13287-13292 (1997).
48. D. Games, D. Adams, R. Alessandrini, R. Barbour, P. Berthelette, C. Blackwell, T. Carr, J. Clemens, T. Donaldson, and F. Gillespie, Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein, Nature 373, 523-527 (1995).
49. K.K. Hsiao, P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, F. Yang, and G. Cole, Correlative memory deficits, Aβ elevations, and amyloid plaques in transgenic mice, Science 274, 99-102 (1996).
50. D.Morgan, Learning and memory deficits in APP transgenic mouse models of amyloid deposition, Neurochem Res 28, 1029-1034 (2003).
51. S.A. Frautschy, F.S. Yang, M. Irrizarry, B. Hyman, T.C. Saido, K. Hsiao, and G.M. Cole, Microglial response to amyloid plaques in APPsw transgenic mice, Am J Pathol 152, 307-317 (1998).
52. L. Holcomb, M.N. Gordon, E. McGowan, X. Yu, S. Benkovic, P. Jantzen, K. Wright, I. Saad, R. Mueller, D. Morgan, S. Sanders, C. Zehr, K. O'Campo, J. Hardy, C.M. Prada, C. Eckman, S. Younkin, K. Hsiao, and K. Duff, Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes, Nat Med 4, 97-100 (1998).
53. J. Apelt and R. Schliebs, Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology, Brain Res 894, 21-30 (2001).
54. Y. Matsuoka, M. Picciano, B. Malester, J. LaFrancois, C. Zehr, J.M. Daeschner, J.A. Olschowka, M.I. Fonseca, M.K. O'Banion, A.J. Tenner, C.A. Lemere, and K. Duff, Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease, Am J Pathol 158, 1345-1354 (2001).
55. M.C. Irizarry, F. Soriano, M. McNamara, K.J. Page, D. Schenk, D. Games, and B.T. Hyman, Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse, J Neurosci 17, 7053-7059 (1997).
56. A. Takeuchi, M.C. Irizarry, K. Duff, T.C. Saido, A.K. Hsiao, M. Hasegawa, D.M. Mann, B.T. Hyman, and T. Iwatsubo, Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss, Am J Pathol 157, 331-339 (2000).
57. P. Chapman, G.L. White, M.W. Jones, D. Cooper-Blacketer, V.J. Marshall, M. Irizarry, L. Younkin, M.A. Good, T.V.P. Bliss, B.T. Hyman, S.G. Younkin, and K.K. Hsiao, Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice, Nat Neurosci 2, 271-276 (1999).
58. M. Botto, C1q knock-out mice for the study of complement deficiency in autoimmune disease, Exp Clin Immunogenet 15, 231-234 (1998).
59. M. Botto, C. Dell'agnola, A.E. Bygrave, E.M. Thompson, H.T. Cook, F. Petry, M. Loos, P.P. Pandolfi, and M.J. Walport, Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies, Nat Genet 19, 56-59 (1998).
60. M.I. Fonseca, J. Zhou, M. Botto, and A.J. Tenner, Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease, J Neurosci 24, 6457-6465 (2004).
61. R.D. Terry, E. Masliah, D.P. Salmon, N. Butters, R. DeTeresa, R. Hill, L.A. Hansen, and R. Katzman, Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment, Ann Neurol 30, 572-580 (1991).
62. E. Masliah, M. Mallory, L. Hansen, R. DeTeresa, M. Alford, and R. Terry, Synaptic and neuritic alterations during the progression of Alzheimer's disease, Neurosci Lett 174, 67-72 (1994).
63. H. Cremer, G. Chazal, A. Carleton, C. Goridis, J.D. Vincent, and P.M. Lledo, Long-term but not short-term plasticity at mossy fiber synapses is impaired in neural cell adhesion molecule-deficient mice, Proc Natl Acad Sci USA 95, 13242-13247 (1998).
64. V. Ramirez-Amaya, I. Balderas, J. Sandoval, M.L. Escobar, and F. Bermudez-Rattoni, Spatial long-term memory is related to mossy fiber synaptogenesis, J Neurosci 21, 7340-7348 (2001).
65. D.A. Loeffler, Using animal models to determine the significance of complement activation in Alzheimer's disease, J Neuroinflam 1, 18 (2004).
66. C. Schwab, M. Hosokawa, and P.L. McGeer, Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease, Exp Neurol 188, 52-64 (2004).
67. G.L. Ong and M.J. Mattes, Mouse strains with typical mammalian levels of complement activity, J Immunol Meth 125, 147-158 (1989).
68. R.O. Ebanks and D.E. Isenman, Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity, Mol Immunol 33, 297-309 (1996).
69. A.H. Moore and M.K. O'Banion, Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease, Adv Drug Del Rev 54, 1627-1656 (2002).
70. C.A. Lemere, E.T. Spooner, J.F. Leverone, C. Mori, M. Iglesias, J.K. Bloom, and T.J. Seabrook, Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice, Neurochem Res 28, 1017-1027 (2003).
71. D.J. Selkoe and D. Schenk, Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics, Annu Rev Pharmacol Toxicol 43, 545-584 (2003).
72. R.J. Mead, S.K. Singhrao, J.W. Neal, H. Lassmann, and B.P. Morgan, The membrane attack complex of complement causes severe demyelination associated with acute axonal injury, J Immunol 168, 458-465 (2002).
73. C. Schwab and P.L. McGeer, Complement activated C4d immunoreactive oligodendrocytes delineate small cortical plaques in multiple sclerosis, Exp Neurol 174, 81-88 (2002).
74. P. Gasque, Y.D. Dean, E.P. McGreal, J. VanBeek, and B.P. Morgan, Complement components of the innate immune system in health and disease in the CNS, Immunopharmacology 49, 171-186 (2000).
75. M.L. Shin, H. Rus, and F. Niculescu. Complement system in central nervous system disorders. In The human complement system in health and disease, eds. J.E. Volanakis and M.M. Frank, pp. 499-525. New York: Marcel Dekker Inc., 1998.
76. K.D. Whitney and J.O. McNamara, GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins, J Neurosci 20, 7307-7316 (2000).
77. A. Rostagno, T. Revesz, T. Lashley, Y. Tomidokoro, L. Magnotti, H. Braendgaard, G. Plant, M. Bojsen-Moller, J. Holton, B. Frangione, and J. Ghiso, Complement activation in chromosome 13 dementias: similarities with Alzheimer's disease, J Biol Chem 277, 49782-49790 (2002).
78. L.V. Johnson, W.P. Leitner, A.J. Rivest, M.K. Staples, M.J. Radeke, and D.H. Anderson, The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration, Proc Natl Acad Sci USA (2002).
79. P. Eikelenboom, C. Bate, W.A. van Gool, J.J. Hoozemans, J.M. Rozemuller, R. Veerhuis, and A. Williams, Neuroinflammation in Alzheimer's disease and prion disease, Glia 40, 232-439 (2002).
80. L. Liu, H. Aldskogius, and M. Svensson, Ultrastructural localization of immunoglobulin G and complement C9 in the brain stem and spinal cord following peripheral nerve injury: an immunoelectron microscopic study, J Neurocytol 27, 737-748 (1998).
81. T. Watanabe, T. Yamamoto, Y. Abe, N. Saito, T. Kumagai, and H. Kayama, Differential activation of microglia after experimental spinal cord injury, J Neurotrauma 16, 255-265 (1999).
82. G.S. Hageman, D.H. Anderson, L.V. Johnson, L.S. Hancox, A.J. Taiber, L.I. Hardisty, J.L. Hageman, H.A. Stockman, J.D. Borchardt, K.M. Gehrs, R.J. Smith, G. Silvestri, S.R. Russell, C.C. Klaver, I. Barbazetto, S. Chang, L.A. Yannuzzi, G.R. Barile, J.C. Merriam, R.T. Smith, A.K. Olsh, J. Bergeron, J. Zernant, J.E. Merriam, B. Gold, M. Dean, and R. Allikmets, A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration, Proc Natl Acad Sci USA 102, 7227-7232 (2005).
83. R.J. Klein, C. Zeiss, E.Y. Chew, J.Y. Tsai, R.S. Sackler, C. Haynes, A.K. Henning, J.P. Sangiovanni, S.M. Mane, S.T. Mayne, M.B. Bracken, F.L. Ferris, J. Ott, C. Barnstable, and J. Hoh, Complement factor H polymorphism in age-related macular degeneration, Science (2005).
84. A.O. Edwards, I.R. Ritter, K.J. Abel, A. Manning, C. Panhuysen, and L.A. Farrer, Complement factor H polymorphism and age-related macular degeneration, Science (2005).
85. J.L. Haines, M.A. Hauser, S. Schmidt, W.K. Scott, L.M. Olson, P. Gallins, K.L. Spencer, S.Y. Kwan, M. Noureddine, J.R. Gilbert, N. Schnetz-Boutaud, A. Agarwal, E.A. Postel, and M.A. Pericak-Vance, Complement factor H variant increases the risk of age-related macular degeneration, Science (2005).
86. T. Wyss-Coray, F. Yan, A.H. Lin, J.D. Lambris, J.J. Alexander, R.J. Quigg, and E. Masliah, Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice, Proc Natl Acad Sci USA 99, 10837-10842 (2002).
87. G.M. Pasinetti, G. Tocco, S. Sakhi, W.D. Musleh, M.G. DeSimoni, P. Mascarucci, S. Schreiber, M. Baudry, and C.E. Finch, Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions, Neurobiol Dis 3, 197-204 (1996).
88. S.A. O'Barr, J. Caguioa, D. Gruol, G. Perkins, J.A. Ember, T. Hugli, and N.R. Cooper, Neuronal expression of a functional receptor for the C5a complement activation fragment, J Immunol 166, 4154-4162 (2001).
89. J. Daly and G.J. Kotwal, Proinflammatory complement activation by the Aβ peptide of Alzheimer's disease is biologically significant and can be blocked by Vaccinia virus complement control protein, Neurobiol Aging 19, 619-627 (1998).
90. G. Tocco, W. Musleh, S. Sakhi, S.S. Schreiber, M. Baudry, and G.M. Pasinetti, Complement and glutamate neurotoxicity: genotypic influences of C5 in a mouse model of hippocampal neurodegeneration, Mol Chem Neuropathol 31, 289-300 (1997).
91. S. Okinaga, D. Slattery, A. Humbles, Z. Zsengeller, O. Morteau, M.B. Kinrade, R.M. Brodbeck, J.E. Krause, H.R. Choe, N.P. Gerard, and C. Gerard, C5L2, a non-signaling C5A binding protein, Biochemistry 42, 9406-9415 (2003).
92. S.K. Singhrao, J.W. Neal, B.P. Morgan, and P. Gasque, Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease, Exp Neurol 159, 362-376 (1999).
93. B. Dietzschold, W. Schwaeble, M.K.H. Schäfer, D.C. Hooper, Y.M. Zehng, F. Petry, H. Sheng, T. Fink, M. Loos, H. Koprowski, and E. Weihe, Expression of C1q, a subcomponent of the rat complement system, is dramatically enhanced in brains of rats with either Borna disease or experimental allergic encephalomyelitis, J Neurol Sci 130, 11-16 (1995).
94. S.K. Goldsmith, P. Wals, I. Rozovsky, T.E. Morgan, and C.E. Finch, Kainic acid and decorticating lesions stimulate the synthesis of C1q protein in adult rat brain, J Neurochem 68, 2046-2052 (1997).
95. L. Spielman, D. Winger, L. Ho, P.S. Aisen, E. Shohami, and M. Pasinetti, Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2, Acta Neuropathol (Berl) 103, 157-162 (2002).
96. B.M. Bellander, S.K. Singhrao, M. Ohlsson, P. Mattsson, and M. Svensson, Complement activation in the human brain after traumatic head injury, J Neurotrauma 18, 1295-1311 (2001).
97. C.K. Lee, R. Weindruch, and T.A. Prolla, Gene-expression profile of the ageing brain in mice, Nat Genet 25, 294-297 (2000).
98. B.A. Bahr, K.B. Hoffman, A.J. Yang, U.S. Hess, C.G. Glabe, and G. Lynch, Amyloid β protein is internalized selectively by hippocampal field CA1 and causes neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein, J Comp Neurol 397, 139-147 (1998).
99. R. Fan and A.J. Tenner, Complement C1q expression induced by Abeta in rat hippocampal organotypic slice cultures, Exp Neurol 185, 241-253 (2004).
100. R. Fan and A.J. Tenner, Differential regulation of Abeta42-induced neuronal C1q synthesis and microglial activation, J Neuroinflam. 2, 1 (2005).
101. F. Dandoy-Dron, F. Guillo, L. Benboudjema, J.P. Deslys, C. Lasmezas, D. Dormont, M.G. Tovey, and M. Dron, Gene expression in scrapie: cloning of a new scrapie-responsive gene and the identification of increased levels of seven other mRNA transcripts, J Biol Chem 273, 7691-7697 (1998).
102. M. Lampert-Etchells, G.M. Pasinetti, C.E. Finch, and S.A. Johnson, Regional localization of cells containing complement C1q and C4 mRNAs in the frontal cortex during Alzheimer's disease, Neurodegeneration 2, 111-121 (1993).
103. x-glycosylated complement inhibitory protein, Science 285, 595-599 (1999).
104. K. Terai, D.G. Walker, E.G. McGeer, and P.L. McGeer, Neurons express proteins of the classical complement pathway in Alzheimer disease, Brain Res 769, 385-390 (1997).
105. K. Yasojima, C. Schwab, E.G. McGeer, and P.L. McGeer, Up-regulated production and activation of the complement system in Alzheimer's disease brain, Am J Pathol 154, 927-936 (1999).
106. K. Ohmi, D.S. Greenberg, K.S. Rajavel, S. Ryazantsev, H.H. Li, and E.F. Neufeld, Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB, Proc Natl Acad Sci USA 100, 1902-1907 (2003).
107. A. Reboul, M.H. Prandini, J.C. Bensa, and M.G. Colomb, Characterization of C1q, C1s and C1 Inh synthesized by stimulated human monocytes in vitro, FEBS Lett 190, 65-68 (1985).
108. S.D. Webster, M.D. Galvan, E. Ferran, W. Garzon-Rodriguez, C.G. Glabe, and A.J. Tenner, Antibody-mediated phagocytosis of the amyloid β-peptide in microglia is differentially modulated by C1q, J Immunol 166, 7496-7503 (2001).
109. S.S. Bohlson, M. Zhang, C.E. Ortiz, and A.J. Tenner, CD93 interacts with the PDZ domain-containing adaptor protein GIPC: implications in the modulation of phagocytosis, J Leukoc Biol 77, 80-89 (2005).
110. C.A. Ogden, A. deCathelineau, P.R. Hoffmann, D. Bratton, B. Ghebrehiwet, V.A. Fadok, and P.M. Henson, C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells, J Exp Med 194, 781-796 (2001).
111. L.C. Korb and J.M. Ahearn, C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited, J Immunol 158, 4525-4528 (1997).
112. J.S. Navratil, S.C. Watkins, J.J. Wisnieski, and J.M. Ahearn, The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells, J Immunol 166, 3231-3239 (2001).
113. A.J. Nauta, A. Roos, and M.R. Daha, A regulatory role for complement in innate immunity and autoimmunity, Int Arch Allergy Immunol 134, 310-323 (2004).
114. M. Botto and M.J. Walport, C1q, autoimmunity and apoptosis, Immunobiology 205, 395-406 (2002).
115. D.A. Mitchell, M.C. Pickering, J. Warren, L. Fossati-Jimack, J. Cortes-Hernandez, H.T. Cook, M. Botto, and M.J. Walport, C1q deficiency and autoimmunity: the effects of genetic background on disease expression, J Immunol 168, 2538-2543 (2002).
116. Y. Miura-Shimura, K. Nakamura, M. Ohtsuji, H. Tomita, Y. Jiang, M. Abe, D. Zhang, Y. Hamano, H. Tsuda, H. Hashimoto, H. Nishimura, S. Taki, T. Shirai, and S. Hirose, C1q regulatory region polymorphism down-regulating murine c1q protein levels with linkage to lupus nephritis, J Immunol 169, 1334-1339 (2002).
117. B.G.J.M. Bolscher, R. van Zwieten, I.M. Kramer, R.S. Weening, A.J. Verhoeven, and D. Roos, A phosphoprotein of Mr 47,000, defective in autosomal chronic granulomatous disease, copurifies with one of two soluble components required for NADPH:02 oxidoreductase activity in human neutrophils, J Clin Invest 83, 757-763 (1989).
118. R.J. Quigg, Y. Kozono, D. Berthiaume, A. Lim, D.J. Salant, A. Weinfeld, P. Griffin, E. Kremmer, and V.M. Holers, Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor, J Immunol 160, 4553-4560 (1998).
119. H.F. Weisman, T. Bartow, M.K. Leppo Jr., H.C. Marsh, G.R. Carson, M.F. Concino, M.P. Boyle, K.H. Roux, M.L. Weisfeldt, and D.T. Fearon, Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis, Science 249, 146-151 (1990).
120. L. Bergamaschini, E. Rossi, C. Storini, S. Pizzimenti, M. Distaso, C. Perego, A. De Luigi, C. Vergani, and D.S. Grazia, Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease, J Neurosci 24, 4181-4186 (2004).
121. A.M. Soulika, M.M. Khan, T. Hattori, F.W. Bowen, B.A. Richardson, C.E. Hack, A. Sahu, L.H. Edmunds Jr., and J.D. Lambris, Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons, Clin Immunol 96, 212-221 (2000).
122. D. Mastellos, D. Morikis, C. Strey, M.C. Holland, and J.D. Lambris, From atoms to systems: a cross-disciplinary approach to complement-mediated functions, Mol Immunol 41, 153-164 (2004).
123. M. Otto, H. Hawlisch, P.N. Monk, M. Muller, A. Klos, C.L. Karp, and J. Kohl, C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism, J Biol Chem 279, 142-151 (2004).
124. T.M. Woodruff, T.V. Arumugam, I.A. Shiels, R.C. Reid, D.P. Fairlie, and S.M. Taylor, Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats, J Surg Res 116, 81-90 (2004).
125. H. Hawlisch, M. Wills-Karp, C.L. Karp, and J. Kohl, The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma, Mol Immunol 41, 123-131 (2004).
126. D. Spitzer, J. Unsinger, D. Mao, X. Wu, H. Molina, and J.P. Atkinson. ScF-Crry confers resistance against complement-mediated desctruction of Crry deficient RBCs in an in vivo muse model. Mol Immunol 41, 310 (2004).
127. M. Sarvari, I. Vago, C.S. Weber, J. Nagy, P. Gal, M. Mak, J.P. Kosa, P. Zavodszky, and T. Pazmany, Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity, J Neuroimmunol 137, 12-18 (2003).
128. C.W. Cotman, A.J. Tenner, and B.J. Cummings, β-amyloid converts an acute phase injury response to chronic injury responses, Neurobiol Aging 17, 723-731 (1996).
129. E.G. McGeer and P.L. McGeer, Inflammatory processes in Alzheimer's disease, Prog Neuropsychopharmacol Biol Psychiatry 27, 741-749 (2003).
130. R. Veerhuis, P. Van der Valk, I. Janssen, S.S. Zhan, W.E. VanNostrand, and P. Eikelenboom, Complement activation in amyloid plaques in Alzheimer's disease brains does not proceed further than C3, Virchows Arch 426, 603-610 (1995).